Narrative review / 2017
An expert panel issued consensus recommendations on using lipid-lowering nutraceuticals to manage dyslipidemia in clinical practice.
An International Lipid Expert Panel developed a position paper to provide consensus-based recommendations on lipid-lowering nutraceuticals for dyslipidemia management. Available data suggest nutraceuticals may help patients achieve lipid targets, reduce residual cardiovascular risk, and improve early vascular markers like endothelial function and pulse wave velocity. However, the authors note that clinical evidence for individual or combined nutraceuticals is largely variable, very limited for many agents, and often debatable.
- Study type
- Consensus position paper
- Who was studied
- Patients with dyslipidemia (not on statins, not at goal, or statin-intolerant)
- What was measured
- Dyslipidemia management and cardiovascular residual risk reduction
THE PAPER
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.
Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Nutr Rev, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.